Kapp N, Curtis KM. Hormonal contraceptive use among women with liver tumors: a systematic review. Contraception. 2009;80(4):387–90.
McCoy SI, Zheng W, Montgomery ET, Blanchard K, van der Straten A, de Bruyn G, et al. Oral and injectable contraception use and risk of HIV acquisition among women in sub-Saharan Africa. AIDS. 2013;27(6):1001–9.
Westoff C, Truman C. Depressive symptoms and Depo-Provera. Contraception. 1998;57(4):237–40.
Culwell KR, Curtis KM, del Carmen Cravioto M. Safety of contraceptive method use among women with systemic lupus erythematosus: a systematic review. Obstet Gynecol. 2009;114(2 Pt 1):341–53.
World Health Organization. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. Contraception. 1998;57:315–24.
Pardthaisong T, Yenchit C, Gray R. The long-term growth and development of children exposed to Depo- Provera during pregnancy or lactation. Contraception. 1992;45:313–24.
Brownell EA, Fernandez ID, Fisher SG, Howard CR, Ternullo SR, Lawrence RA, et al. The effect of immediate postpartum depot medroxyprogesterone on early breastfeeding cessation. Contraception. 2013;87(6):836–43.
Baheiraei A, Ardsetani N, Ghazizadeh S. Effects of progestogen-only contraceptives on breast-feeding and infant growth. Int J Gynaecol Obstet. 2001;74(2):203–5.
Progestogen-only contraceptives during lactation: I. Infant growth. World Health Organization Task force for Epidemiological Research on Reproductive Health; Special Programme of Research, Development and Research Training in Human Reproduction. Cont
Westhoff C, Jain JK, Milsom I, Ray A. Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mL. Contraception. 2007;75(4):261–7.
Kaunitz AM, Darney PD, Ross D, Wolter KD, Speroff L. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density. Contraception. 2009;80(1):7–17.
Jain J, Jakimiuk AJ, Bode FR, Ross D, Kaunitz AM. Contraceptive efficacy and safety of DMPA-SC. Contraception. 2004;70(4):269–75.
Steenland MW, Zapata LB, Brahmi D, Marchbanks PA, Curtis KM. The effect of follow-up visits or contacts after contraceptive initiation on method continuation and correct use. Contraception. 2013;87(5):625–30. doi:10.1016/j.contraception.2012.09.018.
Steenland MW, Zapata LB, Brahmi D, Marchbanks P, Curtis KM. Appropriate follow up to detect potential adverse events after initiation of select contraceptive methods: a systematic review. Contraception. 2013;87(5):611–24. doi:10.1016/j.contraception.
Tepper NK, Steenland MW, Marchbanks PA, Curtis KM. Laboratory screening prior to initiating contraception: a systematic review. Contraception. 2013;87(5):645–9. doi:10.1016/j.contraception.2012.08.009.
Tepper NK, Curtis KM, Steenland MW, Marchbanks PA. Physical examination prior to initiating hormonal contraception: a systematic review. Contraception. 2013;87(5):650–4. doi:10.1016/j.contraception.2012.08.010.
Tepper NK, Curtis KM, Steenland MW, Marchbanks PA. Blood pressure measurement prior to initiating hormonal contraception: a systematic review. Contraception. 2013;87(5):631–8. doi:10.1016/j.contraception.2012.08.025.
Tantiwattanakul P, Taneepanichskul S. Effect of mefenamic acid on controlling irregular uterine bleeding in DMPA users. Contraception. 2004;70(4):277–9. doi:10.1016/j. contraception.2004.04.003.
Nathirojanakun P, Taneepanichskul S, Sappakitkumjorn N. Efficacy of a selective COX-2 inhibitor for controlling irregular uterine bleeding in DMPA users. Contraception. 2006;73(6):584–7. doi:10.1016/j.contraception.2005.09.013.
Sapire KE. A study of bleeding patterns with two injectable contraceptives given postpartum and the effect of two nonhormonal treatments. Adv Contracept. 1991;7(4):379–87.
Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depot medroxyprogesterone acetate for contraception.
Full citation: Said S, Sadek W, Rocca M, Koetsawang S, Kirwat O, Piya-Anant M et al. Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depot medroxyprogesterone acetate for contraception. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force…
Parker RA, McDaniel EB. The use of quinesterol for the control of vaginal bleeding irregularities caused by DMPA. Contraception. 1980;22(1):1–7.
Jain JK, Nicosia AF, Nucatola DL, Lu JJ, Kuo J, Felix JC. Mifepristone for the prevention of breakthrough bleeding in new starters of depo-medroxyprogesterone acetate. Steroids. 2003;68(10–13):1115–9.
Harel Z, Biro F, Kollar L, Riggs S, Flanagan P, Vaz R. Supplementation with vitamin C and/or vitamin B(6) in the prevention of Depo-Provera side effects in adolescents. J Pediatr Adolesc Gynecol. 2002;15(3):153–8.
Goldberg AB, Cardenas LH, Hubbard AE, Darney PD. Post-abortion depot medroxyprogesterone acetate continuation rates: a randomized trial of cyclic estradiol. Contraception. 2002;66(4):215–20.
Paulen ME, Curtis KM. When can a woman have repeat progestogen-only injectables – depot medroxyprogesterone acetate or norethisterone enantate? Contraception. 2009;80(4):391–408. doi:10.1016/j.contraception.2009.03.023.
Kapp N, Gaffield ME. Initiation of progestogen-only injectables on different days of the menstrual cycle and its effect on contraceptive effectiveness and compliance: a systematic review. Contraception. 2013;87(5):576–82. doi:10.1016/j.contraception.
Halpern V, Combes SL, Dorflinger LJ, Weiner DH, Archer DF. Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm. Contraception. 2014;89(1):31–5. doi:10.1016/j.contraception.2013.07.002.
Kingsley F and Salem RM. Essential Knowledge about Injectable Contraceptives. Injectables Toolkit, 2017.
DMPA-SC Resource Library (2020)
This online resource library created by the PATH-JSI DMPA-SC Access Collaborative includes communications guidance and training resources in both English and French, including classroom-based training materials, videos, and an eLearning course. The site also includes DMPA-SC evidence, product introduction and scale-up information, advocacy tools, and more
Family Planning for Adolescents and Women at High Risk for HIV (2021)
Family Planning for Adolescents and Women at High Risk for HIV (2021) is a supplement to Family Planning: A Global Handbook for Providers that outlines guidance for offering family planning to women and girls in high HIV burden settings, in alignment with WHO recommendations on contraceptive eligibility for women at high risk of HIV.
Balanced Counseling Strategy Plus (BCS+)
A practical, interactive, client-friendly counseling strategy that uses three key job aids (visual memory aids) for counseling clients about family planning to clients living in areas with high rates of HIV and STIs.
The WHO Medical Eligibility Criteria Wheel for Contraceptive Use (2015)
A tool that makes it easy to identify medical eligibility for use of family planning methods. A digital app version is also available for free download.
The Selected Practice Recommendations for Contraceptive Use (3rd Edition 2016)
This resource provides guidance on how to use contraceptive methods safely and effectively, once they are deemed to be medically appropriate.
The Medical Eligibility Criteria for Contraceptive Use (5th edition 2015)
This resource provides guidance on whether people with certain medical conditions can safely and effectively use specific contraceptive methods.
Family Planning: A Global Handbook for Providers (2022 update).
This book serves as a quick-reference resource for all level of health care workers. It provides practical guidance on delivering family planning methods appropriately and effectively
